MAFLD Pandemic: Updates in Pharmacotherapeutic Approach Development

Published: May 30, 2024

With around one billion of the world's population affected, era Metabolic-associated fatty liver disease (MAFLD) pandemic has entered global stage. MAFLD is a chronic progressive with accompanying metabolic disorders such as type 2 diabetes mellitus and obesity which can progress asymptomatically to cirrhosis subsequently hepatocellular carcinoma (HCC), for which, date there almost no approved pharmacologic options. Because very complex etiology it affects also extrahepatic organs, multidisciplinary approach required when comes finding an effective safe active substance treatment. The optimal drug should diminish steatosis, fibrosis inflammation in liver, winner authorisation seems be that significantly improves histology. Saroglitazar (Lipaglyn®) was Metabolic dysfunction associated steatohepatitis (MASH) India 2020; however, still being investigated other countries. Despite pharmaceutical industry lagging behind develop ap-proved therapy MAFLD, research been recently intensified many molecules are underway final stages clinical trials expected coming few years. Already this year, first (Rezdiffra™) United States via accelerated procedure treatment i.e. MASH adults. This review underscores most recent information related development drugs treatment, focusing on have come furthest towards approval.

Language: Английский

---

Lipid sensing by PPARα: Role in controlling hepatocyte gene regulatory networks and the metabolic response to fasting

Progress in Lipid Research, Journal Year: 2024, Volume and Issue: 96, P. 101303 - 101303

Published: Nov. 1, 2024

Peroxisome proliferator-activated receptors (PPARs) constitute a small family of three nuclear that act as lipid sensors, and thereby regulate the transcription genes having key roles in hepatic whole-body energy homeostasis, other processes (e.g., inflammation), which have far-reaching health consequences. receptor isotype α (PPARα) is expressed oxidative tissues, particularly liver, carrying out critical functions during adaptive fasting response. Advanced omics technologies provided insight into vast complexity regulation PPAR expression activity, well their downstream effects on physiology liver its associated metabolic organs. Here, we provide an overview gene regulatory networks controlled by PPARα response to fasting. We discuss impacts metabolism, systemic repercussions benefits PPARα-regulated ketogenesis production fibroblast growth factor 21 (FGF21), fasting- stress-inducible hormone. also highlight current challenges using novel methods further improve our knowledge disease.

Language: Английский

---

Dawn of an era of effective treatments for MAFLD

Portal hypertension & cirrhosis, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 24, 2024

Abstract Fatty liver disease is a commonly occurring resulting in hepatic and extrahepatic complications. To date, there have been few available treatments beyond conventional lifestyle modification. While modifications weight loss >10% shown to be beneficial for metabolic dysfunction‐associated steatohepatitis (MASH), the majority of patients, this difficult achieve. The recent approval resmetirom (a thyroid hormone receptor beta agonist) by Food Drug Administration following positive results histological outcomes phase 3 trial has opened door new (dysfunction)‐associated fatty (MAFLD) MASH. There are currently number trials targeting variety signaling pathways involved pathogenesis that also promising. This review focuses on MAFLD MASH, ongoing clinical trials, unresolved controversies area.

Language: Английский

---

Multi‐target Drugs to Treat Metabolic Diseases

Published: Dec. 27, 2024

Language: Английский

---

Cardamom consumption may improve cardiovascular metabolic biomarkers in adults: A systematic review and meta-analysis of randomized controlled trials

Nutrition Research, Journal Year: 2024, Volume and Issue: 125, P. 101 - 112

Published: March 12, 2024

Language: Английский

---